PDS Biotechnology Corp.
3 clinical trials · Sponsor
◉ Watch PDS Biotechnology Corp.
| Record | Firm | Date |
|---|---|---|
| Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (NCT06790966) | PDS Biotechnology Corp. | 2025-05-30 |
| Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC (NCT04260126) | PDS Biotechnology Corp. | 2021-03-29 |
| An Open-Label, Phase I, Escalating Dose Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of PDS0101 (NCT02065973) | PDS Biotechnology Corp. | 2014-02-01 |
Track PDS Biotechnology Corp. automatically
Every clearance here is in the API, with alerts when new ones post.